By Emmanuelle Trombe, co-head of McDermott Will & Schulte’s Life Sciences industry practice
The life sciences and healthcare sector is entering a new phase marked by both increased complexity and significant opportunity.
While it remains one of the most resilient and value-generating industries globally, the conditions underpinning that success are evolving.
Recent discussions, including those at our European Health & Life Sciences Symposium 2026, highlight how market dynamics, capital allocation, private equity strategies and the rapid rise of AI are reshaping the landscape.
As Sharon Lamb, head of McDermott’s UK Health and Life Sciences Practice Group, noted, “Life sciences is entering a new era where innovation alone is no longer enough and success will be defined by how effectively organisations execute across capital, technology and increasingly complex market dynamics.”
This shift is already visible across the sector.
Growth will increasingly depend on how effectively organisations navigate pricing pressures, deploy capital, scale innovation and adopt new technologies at speed. Set against this backdrop, six defining shifts are reshaping the sector.
From innovation-led growth to geopolitically shaped markets
Scientific breakthroughs and new modalities continue to drive progress, but they are no longer the sole determinants of growth.
Politics, pricing and geopolitics are now central forces shaping industry economics. Healthcare spending continues to outpace GDP across developed markets, intensifying scrutiny on pricing.
At the same time, the global industry remains structurally dependent on US pricing despite sustained downward pressure on net prices, and policy scenarios such as international price benchmarking point to the risk of significant profit compression.
Compounding this, loss of exclusivity is accelerating, creating a substantial pipeline replenishment challenge.
The scale of revenue at risk over the next five years is materially higher than in the previous five, increasing reliance on external innovation and dealmaking.
The result is a more constrained environment where growth, pricing and policy are increasingly intertwined.
The return of scale and the repricing of healthcare
After a decade in which innovation was concentrated in specialty areas such as oncology and immunology, the industry is shifting back toward high-prevalence, large-scale disease areas, partly driven by the success of GLP-1 therapies.
This shift brings both opportunity and tension: larger addressable markets and broader patient populations, alongside increased pressure on healthcare systems and reimbursement models.
It also introduces delivery challenges that require more scalable, digital-first care models.
At the same time, consumer behaviour is evolving, with patients increasingly willing to pay out of pocket for treatments that offer tangible quality-of-life benefits.
This is accelerating the rise of more consumer-centric healthcare delivery. The industry must therefore balance scale-driven growth with affordability and delivery constraints.
Capital innovation becomes a strategic advantage
Traditional funding models such as venture capital, strategic partnerships and public markets are now complemented by a more complex and flexible capital ecosystem.
This includes private credit and structured capital providers, royalty and revenue-contingent financing, sovereign and long-duration capital, and public-private funding partnerships.
As Aymen Mahmoud, managing partner of McDermott’s London office and head of the firm’s European finance practice, observed, “Innovation in financing is doing both, expanding the capital pool and redistributing risk with far greater precision.
Structures like royalty and milestone driven financings are attracting new investors, particularly into the underfunded space between clinical validation and commercial scale, where traditional capital is often constrained.
At the same time, increased competition for high-quality assets and the amount of dry powder in the market are driving more sophisticated structures that disaggregate risk and allocate it more precisely across the value chain.”
Capital is becoming more targeted and specialised. Equity continues to dominate early-stage, high-risk innovation, while structured and non-dilutive capital is increasingly used at later stages.
Financing strategies are more closely aligned to specific assets, risks and development phases, alongside a shift toward longer-horizon capital planning that enables companies to reach more meaningful value inflection points before returning to market.
Despite this progress, funding gaps remain, particularly in Europe, where companies often struggle to secure capital between early discovery and clinical proof of concept.
In this environment, capital strategy has become a core capability and a key competitive differentiator.
A more selective, operational private equity playbook
Private equity in healthcare remains highly attractive, but the investment environment has become more disciplined on pricing, more selective in asset selection and more complex in execution.
The market is increasingly bifurcated, with high-quality, defensible assets continuing to attract strong demand, while less differentiated businesses face longer processes, valuation gaps and more structured deal terms.
In response, private equity firms are shifting toward operational value creation rather than financial engineering.
There is greater focus on leadership, pricing, M&A and execution, alongside more flexible deal structures such as continuation vehicles and structured equity.
At the same time, investors are specialising in specific sub-sectors where they can build deeper expertise.
In a tighter market, execution, discipline and defensibility are becoming the defining factors for success.
AI is transforming the industry, but adoption is the real disruption
Artificial intelligence is reshaping life sciences and healthcare across the value chain.
It is accelerating drug discovery and development, enhancing diagnostics and enabling personalised medicine, reducing administrative burden, improving clinical workflows, and unlocking new models of patient engagement and care delivery.
What stands out is not only the capability of AI, but the speed of its adoption by clinicians, organisations and patients. This rapid uptake is driven by immediate, tangible benefits such as time savings and decision support.
Its value is also becoming clearer in less visible areas, including workflow automation, data structuring and interoperability, and operational efficiency across healthcare systems.
However, a gap remains between adoption and measurable financial impact, and challenges around trust, validation and integration persist.
Competitive advantage will therefore depend on practical, scalable implementation and demonstrable outcomes.
Data, infrastructure and regulation will define the next winners
As AI scales, the foundations of value creation are shifting. Much of healthcare data remains unstructured and underutilised, and unlocking it is essential to enabling AI at scale.
At the same time, the rise of foundation models and agentic AI is changing how solutions are built, favouring platforms and ecosystems over standalone tools.
The ability to embed AI into clinical workflows and healthcare systems will ultimately determine real-world impact.
Regulation is also emerging as a defining variable. Frameworks are struggling to keep pace with technological change, and fragmentation across geographies is increasing complexity.
Europe, in particular, faces the challenge of balancing innovation with regulation. Future leaders will be those who can combine data access, technological capability and regulatory navigation at scale.
Conclusion: A new playbook for life sciences leaders
The life sciences sector is not slowing down, but it is becoming more demanding.
Success in this next phase will depend on the ability to combine differentiated science with disciplined execution and strategic capital deployment.
Overlaying all of this is the accelerating impact of AI, which is reshaping how innovation is created, delivered and monetised.
The result is a fundamental shift: the next generation of leaders will be defined not by innovation alone, but by their ability to navigate complexity across markets, capital and technology with greater speed, precision and effectiveness than their peers.
Listen: A new era for kidney cancer care?
